Screener
Protagonist Therapeutics PTGX Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Protagonist Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: Protagonist Therapeutics’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 4:17 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091123
FAQ
- What is Protagonist Therapeutics's cash & equivalents?
- Protagonist Therapeutics (PTGX) reported cash & equivalents of $420.08M in Q2 2026.
- How has Protagonist Therapeutics's cash & equivalents changed year-over-year?
- Protagonist Therapeutics's cash & equivalents increased by 149.2% year-over-year, from $168.54M to $420.08M.
- What is the long-term trend for Protagonist Therapeutics's cash & equivalents?
- Over 5 years (2020 to 2025), Protagonist Therapeutics's cash & equivalents has grown at a 1.8% compound annual growth rate (CAGR), from $117.36M to $128.39M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Protagonist Therapeutics's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude